Catalyst Wire Dossier Catalyst Wire Dossier

Imipenem/Cilastatin-XNW4107

· Evopoint Biosciences Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Imipenem/Cilastatin-XNW4107, covering 2023-02-16 to 2025-11-06. Get the full timeline:

Most recent: Clinical Trial Update: Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2) [Phase 3]

See pricing